✨ A big thank you to everyone for such a wonderful and inspiring day at the 𝟭𝟬𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗚𝗣𝗔 𝗦𝘁𝘂𝗱𝘆 𝗚𝗿𝗼𝘂𝗽 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 hosted in the magnificent setting of the Maison de l’Amérique Latine, Paris🇫🇷 A unique opportunity for exchange and collaboration🤝

🔬 Don’t miss this article! 🧬 Led and promoted by Prof. Terrier’s group, this important randomized trial evaluates rituximab vs conventional therapy (glucocorticoids ± cyclophosphamide) for remission induction in EGPA! ➡️

What a meaningful and inspiring day at the 𝗔𝗣𝗔𝗖𝗦 𝟮𝟬𝟮𝟱 𝗗𝗼𝗰𝘁𝗼𝗿𝘀–𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 in Padua! 🩷 A huge thank you to everyone for their enthusiasm and for the valuable testimonials from patients! So grateful to share within such a supportive community!

🌤️ A wonderful day has started here in Padua! The European EGPA Study Group is delighted to join the APACS Doctors–Patients Meeting, a day of connection, shared experiences, and care and awareness for everyone living with EGPA.🩺💬 We’re here today! 🎯

𝗦𝗲𝗲 𝘆𝗼𝘂 𝗶𝗻 𝗟𝗼𝗻𝗱𝗼𝗻 𝗶𝗻 𝟮𝟬𝟮𝟲! 🇬🇧✨ #EuropeanEGPAstudyGroupMeeting #EESG2026

𝟭𝟬𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗚𝗣𝗔 𝗦𝘁𝘂𝗱𝘆 𝗚𝗿𝗼𝘂𝗽 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 - part 3

𝟭𝟬𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗚𝗣𝗔 𝗦𝘁𝘂𝗱𝘆 𝗚𝗿𝗼𝘂𝗽 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 - part 2

𝟭𝟬𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗚𝗣𝗔 𝗦𝘁𝘂𝗱𝘆 𝗚𝗿𝗼𝘂𝗽 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 - part 1

Thrilled to share our latest RCT in #EGPA comparing Rituximab Versus Conventional Therapy for Remission Induction, and published in ⁦@AnnalsofIM⁩ - Thanks to all the amazing French Vasculitis Study Group 🙏🙏🙏

Whether you're coming from across the globe or just hopping over from a nearby city, there’s an itinerary to Melbourne with your name on it! Book now to lock in your Australian adventure. Dive into the ultimate Melbourne guide at https://t.co/1i5Om0lttz @MelbConventions

🌏 𝗣𝗹𝗮𝗻 𝘆𝗼𝘂𝗿 𝘁𝗿𝗶𝗽 𝘁𝗼 𝗠𝗲𝗹𝗯𝗼𝘂𝗿𝗻𝗲! 📷 Over 400 flights arrive in Melbourne every week, so you’re sure to find the perfect itinerary! We’ll be there – will you? 📌 Book early to get the best deals and lock in your Australian adventure:

The 𝟮𝟮𝗻𝗱 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗩𝗮𝘀𝗰𝘂𝗹𝗶𝘁𝗶𝘀 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 is coming in February 2026! 🧪 Calling Early Career Scientists & Clinicians! We're excited to share the July E-zine – full of updates and opportunities you won’t want to miss. https://t.co/enJ7OFpx8e

📢 Save the date! 𝟏𝟎𝐭𝐡 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐨𝐟 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐄𝐆𝐏𝐀 𝐒𝐭𝐮𝐝𝐲 𝐆𝐫𝐨𝐮𝐩 📍September 18 – Paris 🔹Free course 🔹50 in-person spots: https://t.co/IS5Q7dn8mC 🔹100 online spots: https://t.co/JGTpTgH2nP 📄Program:

Time is critical in AAV: dampening kidney inflammation prevents damage Why not target effector T cells - leave other T cells alone? Our paper in @NDTSocial defines IL-7Ra as a target https://t.co/EOLHWhFNH1 Anti-IL-7Ra Abs are in Phase 2 trials - alopecia @Q32Bio ?an AAV therapy

📢 Save the date! 𝟏𝟎𝐭𝐡 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐨𝐟 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐄𝐆𝐏𝐀 𝐒𝐭𝐮𝐝𝐲 𝐆𝐫𝐨𝐮𝐩 📍September 18 – Paris 🔹Free course 🔹50 in-person spots: https://t.co/IS5Q7dn8mC 🔹100 online spots: https://t.co/JGTpTgH2nP 📄Program:

🩺 Pilot study tested personalized rituximab spacing in 19 ANCA vasculitis patients based on individual relapse risk after standard 18-month treatment 📅 High-risk patients continued 6-monthly infusions, intermediate-risk received 12-monthly spacing, and low-risk switched to

🧵[1/2] Dr Georg Schett follow up of 🚗 CAR-T cell therapy pilot cohort ⚡️Now 50 patients under treatment, ⚡️Longest follow up of nearly 5 years ➡️ 72 patients year ⚡️92% remission 96% off drugs 2 relapses #EULAR2025 @eular_org

#CarersWeek #Vasculitis #caring for young people diagnosed with vasculitis a #raredisease. An increasing number of younger people and children are being diagnosed. This can have an impact on their #schooling, general behaviour and future fertility. https://t.co/AwyU0ZHl8R

🚨Alert interesting article! 🔥 New study by Sorin et al. in Rheumatology (Oxford) on GC vs GC+CYC in EGPA (without poor prognosis factors) - a valuable addition to the EGPA literature! 📚 #EGPA #vasculitis https://t.co/Ze1U3j6RA0

Don’t miss the latest review published in @NatRevRheumatol on advances in the treatment of ANCA-associated vasculitis (AAV) — a must-read update for anyone! https://t.co/7qmgSxgXvf Many thanks to the authors for their valuable contribution! 👏 #AAV #vasculitis